Infections and Latent Autoimmune Diabetes in Adults

Infections and Genetic Susceptibility in LADA and Type 2 Diabetes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06167616

Acronym

LADA

Enrollment

5048

Registered

2023-12-12

Start date

2010-09-01

Completion date

2019-10-31

Last updated

2023-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Autoimmune Diabetes in Adults, Type 2 Diabetes

Keywords

Latent Autoimmune Diabetes in Adults, Infections, Diabetes Mellitus, Type 2 diabetes, Case-Control Studies, register study

Brief summary

Infections are proposed risk factors for type 1 diabetes in children. The investigators will examine whether a diagnosis of infectious disease also confers an increased risk of latent autoimmune diabetes in adults.

Detailed description

The investigators will use data from a population-based Swedish case-control study (ESTRID) with incident cases of LADA (n=597) and matched controls (n=2386). History of infectious disease are ascertained through national and regional patient registers. The investigators will estimate adjusted odds ratios (OR) with 95% CI for ≥1 respiratory (any/upper/lower), gastrointestinal, herpetic, other or any infectious disease episode, or separately, for 1 and ≥2 infectious disease episodes, within 0-1, 1-3, 3-5 and 5-10 years before LADA diagnosis/matching. Stratified analyses will be performed based on HLA risk genotypes and GADA levels.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 35 years or older, residing in Scania or Uppsala county.

Exclusion criteria

* Less than 35 years

Design outcomes

Primary

Measure	Time frame	Description
LADA	Up to 10 years	≥35 years at diagnosis, GADA positivity (≥10 U/ml) and C-peptide concentrations of ≥0.2 nmol/L (IMMULITE) or ≥0.3 nmol/L (Cobas).

Secondary

Measure	Time frame	Description
Type 2 diabetes	Up to 10 years	also ≥35, GADA negative and had C-peptide concentrations of \>0.60 (IMMULITE)/\>0.72 (Cobas) nmol/L.

Countries

Sweden

Outcome results